Skip to contentA
Acro Biomedical Co., Ltd.
A
ACBMAcro Biomedical Co., Ltd. Q2 2026 · 10-Q
Revenue$0.00$0.00— vs Q2 2025 Net Income-$21.36K-$21.36KN/M vs Q2 2025 EPS Diluted$0.00$0.00— vs Q2 2025 Operating Income-$17,554N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Acro Biomedical Co., Ltd. · CIK 1622996 · Engraved from SEC EDGAR
derived
ended Jun 30, 2026 · filed Aug 14, 2026 · 45 d after period end